SEPARATION AND RELEASE OF CLAIMS AGREEMENTSeparation and Release of Claims Agreement • March 1st, 2017 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
Contract Type FiledMarch 1st, 2017 Company Industry JurisdictionThis Separation and Release of Claims Agreement (the “Agreement”) is made as of the Effective Date (as defined below) between Merrimack Pharmaceuticals, Inc. (the “Company”) and Robert J. Mulroy (“Executive”) (together, the “Parties”).
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 1st, 2017 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledMarch 1st, 2017 Company Industry JurisdictionThis First Amendment to Loan and Security Agreement (this “First Amendment”) is made and entered into as of the latest dated signature on the signature page hereto by and between MERRIMACK PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), and BIOPHARMA CREDIT INVESTMENTS IV SUB, LP, a Cayman Islands exempted limited partnership (“Lender”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 1st, 2017 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
Contract Type FiledMarch 1st, 2017 Company Industry JurisdictionThis Employment Agreement (this “Agreement”), dated as of January 17, 2017, is entered into by and between Merrimack Pharmaceuticals, Inc., a Delaware corporation with a place of business at One Kendall Square, Suite B7201, Cambridge, Massachusetts 02139 (the “Company”), and Richard Peters (the “Employee”).
Amendment No. 8 to SubleaseSublease • March 1st, 2017 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations
Contract Type FiledMarch 1st, 2017 Company IndustryThis Amendment No. 8 (the “Eighth Amendment”) is effective as of January 1, 2017 (the “Eighth Amendment Effective Date”) by and between Silver Creek Pharmaceuticals (“Subtenant”) and FibroGen, Inc. (“FibroGen”). This Eighth Amendment amends the Sublease entered into by and between Subtenant and FibroGen on August 6, 2010 (the “Sublease”), as previously amended (the “Prior Amendments”). Subtenant and FibroGen shall be referred to individually herein as a “Party”, and collectively as, the “Parties”.
LOAN AND SECURITY AGREEMENT Dated as of November 8, 2016Loan and Security Agreement • March 1st, 2017 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledMarch 1st, 2017 Company Industry JurisdictionTHIS LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of November 8, 2016 (the “Effective Date”) by and between MERRIMACK PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), and BIOPHARMA CREDIT INVESTMENTS IV SUB, LP, a Cayman Islands exempted limited partnership (“Lender”), provides the terms on which the Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined). The parties hereto agree as follows: